Katti Jessen

3.0k total citations · 1 hit paper
27 papers, 1.6k citations indexed

About

Katti Jessen is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Katti Jessen has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 15 papers in Oncology and 5 papers in Genetics. Recurrent topics in Katti Jessen's work include PI3K/AKT/mTOR signaling in cancer (13 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Katti Jessen is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (13 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Katti Jessen collaborates with scholars based in United States, Spain and Italy. Katti Jessen's co-authors include Christian Rommel, Michael Martin, Pingda Ren, Matthew R. Janes, Shunyou Wang, Davide Ruggero, Andrew C. Hsieh, Kevan M. Shokat, Michael Bonham and Jonathan S. Weissman and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Katti Jessen

27 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The translational landscape of mTOR signalling steers cancer initiation and metastasis

2012 978 citations Andrew C. Hsieh, Yi Liu et al. Nature profile →

Peers

Countries citing papers authored by Katti Jessen

Since Specialization

Citations

This map shows the geographic impact of Katti Jessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katti Jessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katti Jessen more than expected).

Fields of papers citing papers by Katti Jessen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katti Jessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katti Jessen. The network helps show where Katti Jessen may publish in the future.

Co-authorship network of co-authors of Katti Jessen

This figure shows the co-authorship network connecting the top 25 collaborators of Katti Jessen. A scholar is included among the top collaborators of Katti Jessen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katti Jessen. Katti Jessen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models	Blood	Tiziana Vaisitti, Francesca Arruga et al.	65
2	Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)	Blood	Tiziana Vaisitti, Katti Jessen et al.	9
3	Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)	Blood	George F. Widhopf, Thanh‐Trang Vo et al.	9
4	Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma	Cancer Research	Saravana P. Selvanathan, Garrett T. Graham et al.	8
5	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells	Oncotarget	Zhihong Zeng, Ruiyu Wang et al.	30
6	eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)	Blood	Kevin R. Webster, Vikas Goel et al.	20
7	MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML	Blood	Zhihong Zeng, Ruiyu Wang et al.	2
8	Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function*	Journal of Biological Chemistry	Lomon So, Sung Su Yea et al.	59
9	The translational landscape of mTOR signalling steers cancer initiation and metastasis breakdown →	Nature	Andrew C. Hsieh, Yi Liu et al.	978
10	Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia	Leukemia	Matthew R. Janes, Sharmila Mallya et al.	85
11	Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy	Clinical Cancer Research	Celina García-García, Yasir H. Ibrahim et al.	118
12	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment	Blood	Zhihong Zeng, Yue Shi et al.	97
13	Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer	Cancer Research	Shunyou Wang, Katti Jessen et al.	4
14	Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models	Cancer Research	Celina García-García, Violeta Serra et al.	1
15	Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.	Molecular Cancer Therapeutics	Katti Jessen, Linda Kessler et al.	14
16	Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer	Cancer Research	Shunyou Wang, Katti Jessen et al.	1
17	482 INK128, a potent and selective TORC1/2 inhibitor, demonstrates anti-tumor activity in preclinical models of renal cell carcinoma by a distinct mechanism	European Journal of Cancer Supplements	Katti Jessen, Linda Kessler et al.	1
18	Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.	Gut	Wolff Schmiegel, W. Eberl et al.	48
19	Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.	PubMed	Wolff Schmiegel, W. Eberl et al.	11
20	Pancreatic Oncofetal Antigen in Pancreatic Juices	Scandinavian Journal of Gastroenterology	Wolff Schmiegel, Wolf‐Meinhard Becker et al.	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact